Avoro Capital Advisors LLC
Q4 2021 13F-HR Holdings
Net value change ($000)
-490,274
(-7.7%)
New positions
3
Sold out positions
6
Turnover %
19.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| APLS | 239,707 | 145.5% |
| XBI | 117,558 | NEW |
| BMRN | 102,461 | 70.7% |
| UTHR | 102,063 | 18.4% |
| XENE | 99,959 | 179.2% |
| ARGX | 52,090 | 18.2% |
| SRPT | 50,206 | 21.7% |
| FOLD | 44,838 | 26.6% |
| KRYS | 33,226 | NEW |
| ALNY | 21,810 | 13.6% |
Top Reduces (Value $000, Stocks/ETFs)
| XLRN | -688,400 | -100.0% |
| Mirati Therapeutics, Inc. | -140,098 | -15.8% |
| VRTX | -120,443 | -100.0% |
| Trillium Therapeutics Inc. | -100,092 | -100.0% |
| ARENA PHARMACEUTICALS INC | -89,178 | -43.7% |
| PMVP | -53,323 | -61.2% |
| ASND | -46,532 | -14.7% |
| IOVA | -44,004 | -21.0% |
| Deciphera Pharmaceuticals, Inc. | -36,291 | -100.0% |
| BIIB | -23,771 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
2,910
(0.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|